Table 3 Serious adverse events due to protocol treatment in the sorafenib group and the HAIC group
|  | Sorafenib group (n = 33) | HAIC group (n = 35) | |
|---|---|---|---|
HAIC | sorafenib | ||
(n = 23) | |||
Adverse events | Grade 3/4 | Grade 3/4 | |
n (%) | n (%) | ||
Non-hematological | |||
 Mucositis oral | 1 (3) |  | 1 (4) |
 Hoarseness | 0 (0) |  | 1 (4) |
 Hand-foot skin reaction | 5 (15) |  | 6 (26) |
 Rash | 2 (6) |  | 0 (0) |
 Anorexia | 1 (3) |  | 2 (9) |
 Diarrhea | 1 (3) |  | 0 (0) |
 Bleeding | 1 (3) |  | 1 (4) |
 Fatigue | 1 (3) |  | 1 (4) |
 Hypertension | 6 (18) |  | 8 (35) |
 Somnolence | 1 (3) |  | 0 (0) |
 Weight loss | 1 (3) |  | 0 (0) |
 Abdominal distension | 0 (0) |  | 1 (4) |
 Encephalopathy | 0 (0) | 1 (3) | 0 (0) |
 Nausea | 0 (0) | 1 (3) | 0 (0) |
 Hiccups | 0 (0) | 1 (3) | 0 (0) |
 Absence seizure | 0 (0) | 1 (3) | 0 (0) |
 Hydrocele testis | 0 (0) | 1 (3) | 0 (0) |
Hematological | |||
 Thrombocytopenia | 3 (9) |  | 0 (0) |
 Transaminase elevation | 7 (21) | 3 (9) | 6 (26) |
 Total bilirubin elevation | 2 (6) | 1 (3) | 2 (9) |
 Creatinine elevation | 0 (0) |  | 0 (0) |
 Amylase elevation | 1 (3) |  | 0 (0) |
 Lipase elevation | 9 (27) |  | 4 (17) |
 Liver failure | 1 (3) |  | 0 (0) |
 Hypoalbuminemia | 0 (0) |  | 1 (4) |
 Hyponatremia | 1 (3) |  | 0 (0) |
 Hypophosphatemia | 2 (6) |  | 0 (0) |
Others | |||
 Portal thrombosis | 0 (0) | 1 (3) | 0 (0) |